| Literature DB >> 26640786 |
Rebecca Herzog1, Silvia Tarantino2, András Rudolf3, Christoph Aufricht2, Klaus Kratochwill1, Janusz Witowski3.
Abstract
INTRODUCTION: Senescence of peritoneal mesothelial cells represents a biological program defined by arrested cell growth and altered cell secretory phenotype with potential impact in peritoneal dialysis. This study aims to characterize cellular senescence at the level of global protein expression profiles and modification of proteins with O-linked N-acetylglucosamine (O-GlcNAcylation).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26640786 PMCID: PMC4657062 DOI: 10.1155/2015/382652
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Morphology and senescent phenotype of HPMC. Expression of senescence-associated β-galactosidase (SA-β-Gal) was compared by light microscopy and SA-β-Gal staining in young (a) and senescent ((b) and (c)) HPMC. Magnification (a)-(b): 10x and (c) 40x.
Figure 22D Gel images of young and senescent HPMC. (a) Representative 2D Gel of senescent (left panel) and young (right panel) human peritoneal mesothelial cells (HPMC). (b) Fusion image of 2D protein pattern of senescent and young HPMC (total spot count: 305). Protein spots found statistically significant altered (p < 0.05) in the comparison between senescent and young (n = 29) are marked with spot boundaries, spot label, and name of identified proteins (n = 11).
Figure 3Spot abundance ratio of significantly altered spots (p < 0.05) between young and senescent HPMC. Changes in spot abundance are represented as spot volume ratio for the 29 significantly altered spots found in the comparison between young and senescent human peritoneal mesothelial cells (HPMC).
Identified proteins showing significant differential abundance between young and senescent HPMC cells (p < 0.05) with references of their predicted or reported O-GlcNAcylated sites.
| Protein name | Gene name | SwissProt | MW |
| Lengthc | Spotd | Potential | Se | Te | Predicted | Sf | Tf | Referencesg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actin, cytoplasmic 2 | ACTG1 | ACTG_HUMAN | 41.8 | 5.31 | 375 | 294 | 51 | 25 | 26 | 9 | 8 | 1 | [ |
| Actin, cytoplasmic 1 | ACTB | ACTB_HUMAN | 41.7 | 5.29 | 375 | 294 | 51 | 25 | 26 | 9 | 8 | 1 | [ |
| Keratin, type II cytoskeletal 7 | KRT7 | K2C7_HUMAN | 51.4 | 5.39 | 469 | 52 | 63 | 46 | 17 | 4 | 4 | 0 | — |
| Cofilin-2 | CFL2 | COF2_HUMAN | 18.7 | 7.88 | 166 | 198 | 20 | 12 | 8 | 4 | 4 | 0 | [ |
| Transgelin-2 | TAGLN2 | TAGL2_HUMAN | 22.4 | 8.45 | 199 | 173 | 17 | 7 | 10 | 2 | 2 | 0 | [ |
| 60 kDa heat shock protein, mitochondrial | HSPD1 | CH60_HUMAN | 61.0 | 5.24 | 573 | 19 | 14 | 6 | 8 | 6 | 4 | 2 | [ |
| Heat shock cognate 71 kDa protein | HSPA8 | HSP7C_HUMAN | 70.9 | 5.37 | 646 | 16 | 82 | 35 | 47 | 4 | 2 | 2 | [ |
| Proteasome subunit beta type-2 | PSMB2 | PSB2_HUMAN | 22.8 | 6.52 | 201 | 180 | 18 | 10 | 8 | 9 | 5 | 4 | [ |
| Proteasome subunit beta type-3 | PSMB3 | PSB3_HUMAN | 22.9 | 6.12 | 205 | 150 | 20 | 7 | 13 | 2 | 0 | 2 | — |
| Nucleoside diphosphate kinase A | NME1 | NDKA_HUMAN | 17.1 | 5.82 | 152 | 198 | 11 | 6 | 5 | 3 | 2 | 1 | [ |
| 5′(3′)-deoxyribonucleotidase, cytosolic type | NT5C | NT5C_HUMAN | 23.4 | 6.18 | 201 | 150 | 14 | 6 | 8 | 1 | 0 | 1 | — |
aRelative molecular mass of the protein as calculated from the amino acid sequence of the polypeptide without any co- or posttranslational modifications; bcalculated pI of the protein as obtained from SwissProt database; cnumber of amino acids in the protein sequence; dspots numbered according to Figure 2; epotential O-GlcNAcylation sites expressed as the total number of serine (S) and threonine (T) residues in the protein sequence; fpredicted O-GlcNAcylation sites expressed as the number of predicted serine (S) and threonine (T) residues in the protein, obtained from dbOGAP database using default settings in OGlcNAcScan tool; greferences within protein candidates that have been reported to be O-GlcNAcylated. proteins from the same protein family of the candidate have been reported to be O-GlcNAcylated. [dbOGAP: http://cbsb.lombardi.georgetown.edu/hulab/OGAP.html].
Figure 4O-GlcNAc western blot of young and senescent HPMC. (a) O-GlcNAc specific western blot of young (y) and senescent (s) human peritoneal mesothelial cells (HPMC) from three different donors (HPMC 1–3). (b) Corresponding total protein loading (stain-free technology Bio-Rad).
Figure 5O-GlcNAc western blot of young and senescent HPMC treated with modulators of the hexosamine biosynthesis pathway (HBP). (a) Representative O-GlcNAc specific western blot of young (left) and senescent (right) human peritoneal mesothelial cells (HPMC) treated with O-GlcNAcylation inhibitor (DON) or an inhibitor of the O-GlcNAcase (PUG = PUGNAc). (b) Densitometric analysis of western blots for effects of DON and PUGNAc on O-GlcNAcylation (n = 3). n.s., not significant; p < 0.05 versus control.